Deepcell Names Life Sciences Operations Leader Kevin Farrell as SVP and Head of Operations

Deepcell Names Life Sciences Operations Leader Kevin Farrell as SVP and Head of Operations




Deepcell Names Life Sciences Operations Leader Kevin Farrell as SVP and Head of Operations

MENLO PARK, Calif.–(BUSINESS WIRE)–Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced the appointment of Kevin Farrell as SVP, Operations. Kevin brings to Deepcell over 20 years of operations experience in leadership roles at life science companies, including Berkeley Lights and Standard Biotools (previously known as Fluidigm). His new role is critical for expanding and scaling up operations, including manufacturing and supply chain, to support product commercialization at Deepcell, the creator of an innovative area of single cell biology analysis called morpholomics.

Kevin has had a long and distinguished career in Operations in the life science industry. Prior to joining Deepcell, Kevin was the Head of Business Operations for a molecular diagnostics startup, serving as an executive-in-residence. Previously, he was the Head of Global Operations and Customer Success at Berkeley Lights. Earlier in his career, Kevin spent 17 years in operations at Fluidigm, including three years as SVP, Global Business Operations. He earned his MBA from the Haas School of Business at the University of California, Berkeley.

“Kevin Farrell is a proven, senior-level Operations leader who has guided life science companies through hyper growth, commercialization, organizational development and corporate transformation, with direct responsibilities for people, process and system management. His knowledge, experience and expertise will be an asset for Deepcell as we look to significantly scale up our own operations,” said Maddison Masaeli, CEO and co-founder of Deepcell. “I welcome Kevin to the Deepcell team and the journey we’re on together to transform the understanding and application of cell biology through the newest ‘omic’ on the life science scene – morpholomics.”

“I’m excited to join Deepcell because of its bold vision, first-of-its kind technology, and its phenomenal convergence of scientific experience and engineering talent,” said Kevin Farrell, SVP and Head of Operations at Deepcell. “There is so much potential in Deepcell to establish morpholomics as a technique to generate new insights and to combine with other multi-omic approaches. Deepcell is definitely a company to watch as it brings this novel and enabling technology to market.”

Deepcell was recently recognized as one of the top companies in the Forbes AI 50, a prestigious list of companies leading the way to use artificial intelligence to shape the future. Deepcell’s AI “brain” learns to identify and sort label-free, single cells based on visual features – or morphology – that are barely accessible to the human eye and can continually improve. The company’s AI technology, which includes advancements in microfluidics and high-resolution optics, connects morphology to multiomics, enabling researchers to characterize and gain new insights from single cells at levels of resolution previously unseen with other “omics” based tools.

Deepcell is advancing the use of computational methods with its deep learning capabilities to better understand cellular heterogeneity in richer detail and, thereby, set a new standard for the industry with AI-centric single cell morphology analysis, especially relevant for research, translational research and precision medicine.

About Deepcell

Deepcell is advancing the understanding of cell biology by combining advances in AI and high throughput, quantitative cell classification and capture of single cells to deliver novel insights through an unprecedented view of cell biology. Founded in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features without labeling and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell molecular analysis and can be used to isolate virtually any type of cells, even those occurring at frequencies as low as one in a billion. Deepcell is privately held and based in Menlo Park, CA. For more information, please visit www.deepcell.com.

Contacts

Anthony Petrucci

Bioscribe

anthony@bioscribe.com
512-581-5442